December 12, 2018, MedPage Today
Extending adjuvant endocrine therapy with an aromatase inhibitor to 10 years led to significant improvement in disease-free survival (DFS) and distant (DDFS) in postmenopausal women with hormone receptor-positive (HR-positive) breast cancer, Japanese investigators reported.
Read more.